Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis

doi:10.1007/s13300-022-01350-9

CASIA OpenIR > 多模态人工智能系统全国重点实验室 > 互联网大数据与信息安全

	Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis
	Wang, Hong 1,5; Xie, Xiaoya 2; Zu, Quannan3 ; Lu, Ming 3; Chen, Rongfa 4; Yang, Zhiren 4; Gao, Yongqiang 5; Tang, Zhangui 6
发表期刊	DIABETES THERAPY
ISSN	1869-6953
	2022-12-09
页码	15
通讯作者	Wang, Hong(iriswh2014@163.com)
摘要	Introduction: Type 2 diabetes mellitus (T2DM) is a risk factor for the development of coronary artery disease (CAD). In patients with acute coronary syndrome (ACS), guidelines recommend a potent P2Y12 inhibitor in addition to aspirin. For those with complicated and advanced CAD requiring complex percutaneous coronary intervention (PCI), the risk for adverse ischemic events is even higher. Prolonged dual antiplatelet therapy (DAPT) use is controversial. A new antiplatelet regimen after PCI should be considered. In this analysis, we aimed to systematically show the impact of long-term ticagrelor monotherapy after a short course of DAPT use on the outcomes in patients with T2DM following PCI.Methods: Electronic databases were searched for relevant publications. Studies that were based on patients with T2DM and that included patients with T2DM were selected on the basis of the inclusion and exclusion criteria. Statistical analysis was carried out with RevMan software. The data are presented as risk ratios (RR) with 95% confidence intervals (CI).Results: A total of 8621 patients were included in this analysis, whereby 4357 participants with T2DM were assigned to ticagrelor monotherapy and 4264 were assigned to DAPT. Our results showed long-term ticagrelor monotherapy after a short course of DAPT use to be associated with a significantly lower risk of major adverse cardiac events (RR 0.86, 95% CI 0.77-0.98; P = 0.02) and all-cause mortality (RR 0.77, 95% CI 0.60-0.98; P = 0.03). However, no significant difference was observed in cardiac death, myocardial infarction, stroke, stent thrombosis, or repeated revascularization. Ticagrelor monotherapy was associated with significantly lower risk of thrombolysis in myocardial infarction (TIMI) defined minor or major bleeding (RR 0.71, 95% CI 0.54-0.93; P = 0.01) compared with the DAPT regimen.Conclusion: Long-term ticagrelor monotherapy after a short course of DAPT use showed better results in patients with T2DM following PCI. Therefore, ticagrelor monotherapy after a short course of DAPT use could be considered an evolution in antiplatelet therapy of this decade for the treatment of patients with T2DM after PCI. However, newer studies with a larger population size and cost-effectiveness are factors that should further be considered.
关键词	Percutaneous coronary intervention Type 2 diabetes mellitus Ticagrelor Dual antiplatelet therapy Monotherapy Bleeding
DOI	10.1007/s13300-022-01350-9
关键词[WOS]	DUAL-ANTIPLATELET THERAPY ; SAFETY ; EFFICACY ; ASPIRIN ; TRIALS ; IMPACT
收录类别	SCI
语种	英语
资助项目	Guangxi Key Research and Development Program ; Guangxi Medical and Health Appropriate Technology Development and Promotion Application Project ; Guangxi Nanning Qingxiu District Science and Technology Development Project ; [S2017077] ; [2014S06]
项目资助者	Guangxi Key Research and Development Program ; Guangxi Medical and Health Appropriate Technology Development and Promotion Application Project ; Guangxi Nanning Qingxiu District Science and Technology Development Project
WOS研究方向	Endocrinology & Metabolism
WOS类目	Endocrinology & Metabolism
WOS记录号	WOS:000895663700001
出版者	SPRINGER HEIDELBERG
引用统计	被引频次：1[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.ia.ac.cn/handle/173211/50825
专题	多模态人工智能系统全国重点实验室_互联网大数据与信息安全
通讯作者	Wang, Hong
作者单位	1.Jinan Univ, Guangzhou 510632, Guangdong, Peoples R China 2.Macau Univ Sci & Technol, Macau, Peoples R China 3.Tianjin Univ, Coll Management & Econ, Tianjin 300072, Peoples R China 4.Chinese Acad Sci, Inst Automation, State Key Lab Management & Control Complex Syst, Beijing 100190, Peoples R China 5.Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Cardiol, Nanning 530021, Guangxi, Peoples R China 6.Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Cardiol, Wuhan, Peoples R China
推荐引用方式 GB/T 7714	Wang, Hong,Xie, Xiaoya,Zu, Quannan,et al. Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis[J]. DIABETES THERAPY,2022:15.
APA	Wang, Hong.,Xie, Xiaoya.,Zu, Quannan.,Lu, Ming.,Chen, Rongfa.,...&Tang, Zhangui.(2022).Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis.DIABETES THERAPY,15.
MLA	Wang, Hong,et al."Treatment of the New Era: Long-Term Ticagrelor Monotherapy for the Treatment of Patients with Type 2 Diabetes Mellitus following Percutaneous Coronary Intervention: A Meta-analysis".DIABETES THERAPY (2022):15.